RHONJ's Dolores Catania Gives Weight Loss Drug Warning
RHONJ star Dolores Catania shares weight loss and health update
On her heart procedure, Dolores 'had a condition called AFib, where I was feeling my heart beat out of my chest,' she explained to E! News. She then urged her fans to take their health seriously, warning, 'If you ever feel a flutter in your chest, you need to get that checked. That's not something to ignore.'
Dolores understands that this symptom often mirrors anxiety. However, she continued to press that anyone feeling this symptom must 'go to a cardiologist and get a checkup.' Way to use your platform for good, Dolores!
However, while preparing for her procedure, Dolores had to stop taking Mounjaro. She gained 'probably 15 pounds in over a month.' But, 'Now that I'm back on, I'm healthy and I feel much better,' Dolores explained, noting that she is now 'down 10' pounds.
Following her procedure, Dolores resumed taking Mounjaro, but feelings of nausea hit her almost immediately. Thankfully, Doloroes found a way to help her deal with this pesky little side effect. She now takes Advanced Herbals, a ginger chewable made by Dramamine, which makes her nausea side effects quickly fade away.
Also, never let anyone make you feel bad about taking a weight management pill, Dolores added. 'Don't not do it because you're afraid of what somebody else thinks,' she stressed.
The Real Housewives of New Jersey is available to stream on Peacock and Hayu in the UK and Ireland.
TELL US – ARE YOU GLAD DOLORES IS ISSUING A WARNING TO HER FANS TO GET CHECKED OUT ASAP WHEN THEIR HEALTH IS ON THE LINE?
The post RHONJ's Dolores Catania Gives Weight Loss Drug Warning appeared first on Reality Tea.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
6 minutes ago
- Gizmodo
New Study Bolsters Public Health Case for a Four-Day Work Week
For many of us, Monday is the start of yet another dreary and long work routine. But new trial research out today might highlight a healthier approach to performing our jobs: a permanent four-day workweek. Scientists at Boston College led the study, published Monday in Nature Human Behavior. For six months, the researchers tracked the outcomes of nearly 3,000 workers at 141 businesses after they switched to a four-day workweek with no pay reduction; they also compared them to similar workers at jobs that stuck to a typical schedule. Ultimately, they found that four-day workers reported greater job satisfaction and experienced less burnout than they did before the switch, as well as when compared to people working a five-day week. These improvements were especially apparent in people who reduced their work time by eight or more hours. Gizmodo reached out to study authors Wen Fan and Juliet Schor to discuss the findings in depth, along with the implications they may hold for the future of work. Fan is an associate professor of sociology at Boston College, while Schor is an economist and sociologist at Boston College. The following conversation was lightly edited for clarity and grammar. Ed Cara, Gizmodo: The concept of a four-day workweek has gotten a lot of attention lately, from both workers and scientists. What made your team interested in studying this topic? Schor: We have long histories studying worktime and worker well-being. I wrote a book called The Overworked American many years ago but didn't get the opportunity to study worktime reductions (without pay cuts). Wen has a long history of studying many dimensions of workers' health and well-being, including stress, mental health, etc. She has also studied the impact of disruptive events on health and labor market outcomes. The pandemic was one of those and has been key to creating momentum for the four-day workweek. Fen: I just wanted to add that Juliet was incredibly generous in inviting me to collaborate on this project. Her earlier research on work hours has consistently inspired countless scholars in the field. I think the paper nicely reflects both of our research interests. It has truly been a collaborative effort between the two of us and Orla Kelly, as well as our wonderful research assistant, Guolin Gu, who has run more analyses than we can count! Gizmodo: What were the major takeaways from this latest study? Fen: There are two main findings in this study. First, we find that the four-day workweek improves workers' well-being. This conclusion comes from comparing changes in four well-being indicators between trial companies and control companies. The control companies were those that initially expressed interest in participating but ultimately did not, for various reasons. We found that employees in the trial companies experienced significant reductions in burnout, along with notable improvements in job satisfaction, mental health, and physical health. In contrast, none of these changes were observed among workers in the control companies. The second major finding is about what explains these improvements. We examined various work experiences and health behaviors. We found that three factors played particularly significant roles: work ability (a proxy for workers' self-assessed productivity), sleep problems, and fatigue. In other words, after moving to a four-day workweek, workers saw themselves as more capable, and they experienced fewer sleep problems and lower levels of fatigue, all of which contributed to improved well-being. Gizmodo: What are some of the possible implications of this work? Should more companies offer this option to their employees, for instance? Are there still important questions left to resolve about its benefits and risks, including how widely scalable it can be? Schor: There are many implications of this work—some for workers, others for the organizations and society. This is a rare kind of intervention that can make employees much better off without undermining the viability of the organizations they work for. Our research shows that both the companies and the employees benefit. (This paper is just about the employees, but we also have work showing success for employers.) So yes, we believe many more companies can offer this benefit, and they will do well with it. Their employees will be happier, more loyal, more productive, and less likely to quit. At the same time, the intervention itself is a 'forcing function' that induces improvements for the companies. There are important questions to resolve. One is how it will work at very large companies. We have organizations of up to 5,000 people that are adopting it, but we don't have a very big company in our research. We think it is scalable in that direction, however. We also would like more robust productivity and performance data from the companies. We have some metrics, but they are not complete. We don't think every company can do this right now, but many can. The more challenging ones will be places that have optimized their processes already without resulting in burned-out workers. And we think that some manufacturing companies that are highly exposed to international competition may find it challenging. However, the large majority of workers in our economy are in services/white collar, etc., which are the kinds of companies in our sample. We also think there is great scope for this in healthcare, where burnout is a serious problem. Gizmodo: Do you plan to follow up on the findings? If so, how? And what are some interesting directions that you might want other researchers to explore? Fen: Yes, we have already conducted a follow-up. While the main results in the paper are based on data collected at the six-month mark, we also continued tracking participants six months after the trial ended. We found that all major effects persisted, with well-being indicators remaining significantly higher than their baseline levels. This suggests that the benefits are not just the result of initial enthusiasm or a novelty effect but rather reflect genuine and sustainable change. There are many promising directions for future research. These include testing additional mechanisms that might underlie the well-being benefits, such as workers' perceptions of changes in organizational culture, and exploring how these interventions reshape daily work life. We also encourage researchers to take advantage of similar opportunities to conduct in-depth ethnographic research, which would allow for direct observation of organizational change as it unfolds. This line of work could inform new theories and policy interventions aimed at reimagining the structure of work, with the ultimate goal of enhancing workers' well-being while maintaining organizational performance.
Yahoo
35 minutes ago
- Yahoo
Organ Preservation Market worth $0.3 billion by 2030 with 6.8% CAGR
DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ --The global Organ Preservation Market, valued at US$0.1 billion in 2024 stood at US$0.2 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The organ preservation market is experiencing robust growth fueled by rising incidence of chronic diseases, organ failure, and advancements in transplantation procedures. Increasing rates of end-stage organ conditions—such as kidney, liver, and heart failure—combined with a growing global demand for transplant procedures are key factors accelerating market expansion. The aging population, more susceptible to organ dysfunction, further highlights the increasing need for effective preservation methods to maintain organ viability pre-transplantation. Technological progress in preservation techniques, including hypothermic and normothermic perfusion, is transforming the standard of care by enhancing organ function and extending preservation times. In parallel, developing innovative preservation solutions such as the University of Wisconsin (UW) solution and Custodiol HTK significantly improves transplantation outcomes. Rising awareness among healthcare providers and the public about timely organ donation and preservation is increasing product adoption. Expanding hospital transplant programs, supportive government initiatives, and improved healthcare infrastructure in emerging markets also drive market momentum. Download PDF Brochure: Browse in-depth TOC on "Organ Preservation Market" 300 - Tables 100 - Figures 400 - Pages By solution, the organ preservation market, by solution, is categorized into UW Solution, Custodial HTK, Perfadex, and other solutions (including EuroCollins and Celsior). The UW (University of Wisconsin) solution accounted for the largest market share in 2024. This solution is widely used for preserving and flushing organs such as the liver, kidneys, and pancreas. As the first intracellular solution introduced for this purpose, it has become the benchmark in organ preservation. The dominance of the UW solution can be credited to its high efficacy in improving transplant outcomes. This is primarily due to the inclusion of metabolically inactive compounds like lactobionate and raffinose, which help reduce tissue damage, maintain cellular integrity, and enhance the physiological viability of organs during storage. These advantages have made the UW solution preferred over alternative preservation media. By technique, the static cold storage segment is expected to dominate the market due to its simplicity, cost-effectiveness, and widespread use in preserving kidneys, liver, and pancreas. While newer technologies such as hypothermic machines and normothermic perfusion are gaining traction, especially for heart and lung preservation, static cold storage remains the gold standard in many transplant centers worldwide. In addition, ongoing advancements in perfusion technologies and a growing focus on organ quality optimization before transplantation are expanding the market. The increasing initiatives by governments and non-profits to promote organ donation, along with improvements in preservation solutions and transportation logistics, are further contributing to market growth. As the demand for transplantable organs continues to outpace supply, efficient and advanced preservation methods become more crucial in ensuring transplant success. By organ type, Organ preservation, categorized by organ type, includes kidneys, liver, lungs, heart, and pancreas. In 2024, the kidney segment emerged as the leading contributor to the market. This prominence is primarily due to the rising prevalence of end-stage renal disease (ESRD), for which kidney transplantation remains the most effective treatment option. As kidney failure cases continue to grow, so does the number of transplant procedures, necessitating efficient preservation of donor kidneys before implantation in recipients. By end user, the organ preservation market is divided into transplant centers, hospitals, and specialty clinics. In 2024, the organ transplant centers segment accounted for the largest share of the market. The large share of this segment can be attributed to the extensive establishment of healthcare facilities that operate dedicated transplant programs. These centers are central to organ retrieval, preservation, and transplantation, making them critical consumers of preservation products and technologies. By geography, The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific region is attributed to supportive government policies, rising public awareness regarding organ donation, and a surge in organ donation activities. Countries like China and Japan have implemented standardized national guidelines for organ donation and transplantation, which are playing a key role in advancing the market. Additionally, improvements in healthcare infrastructure, the increasing burden of chronic illnesses, and the rise of medical tourism across several countries in the region are expected to fuel the market growth during the forecast period. Request Sample Pages : The prominent players in the global organ preservation market are Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions, Inc. (US), and TX Innovations (Netherlands). Paragonix (US): Paragonix is the leading market player in organ preservation. It operates mainly in the US and Europe. The company has been focused on developments such as new product launches, partnerships, agreements, and approvals since 2016. The company has developed devices for all thoracic & abdominal organ preservation. Paragonix also focuses on software services and tools for real-time organ tracking. Paragonix partnered with the Lung Transplant Foundation (US) to develop various technologies to improve donor lung preservation. In January 2021, the company partnered with Southwest Transplant Alliance (STA) to provide advanced organ preservation technologies. Such a development proves the company's strong market prevalence. XVIVO Perfusion AB (Sweden) XVIVO Perfusion AB is a prominent market and public domain company. It is headquartered in Sweden and operates in Europe, Asia, the Middle East, and North & South America. It spends nearly 31% of its revenue on R&D, which is why the company is involved in developing improved products for organ perfusion. XVIVO's lung perfusion solution is used mainly in Lung Preservation, making the solution a gold standard. In September 2020, XVIVO Perfusion entered an acquisition agreement with Organ Assist. This agreement further strengthened the company's product range and expanded its addressable market. Dr. Franz Kohler Chemie GmbH (Germany) Dr. Franz Kohler Chemie GmbH is a leading market player in organ preservation solutions since 1959. It involves developing electrolyte solutions, organ-protective solutions, therapeutics, antidotes, X-ray contrast agents, and medical devices. It has captured the market for Custodial, an organ preservation solution. Custodial holds advantages over other solutions, like reduced viscosity and an improved graft survival rate, and is widely used to preserve all organs, unlike other solutions. These advantages of a Custodial solution for organ preservation prove that Dr. Franz Kohler Chemie GMBH holds a substantial market prevalence. For more information, Inquire Now! Related Reports: Biopreservation Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Electrophysiology Market Human Organoids Market Transplant Diagnostics Market Get access to the latest updates on Organ Preservation Companies and Organ Preservation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug
Key Takeaways Sarepta Therapeutics rejected the Food and Drug Administration's call to stop shipments of its muscular dystrophy drug. The FDA request came after a third patient in a Phase 1 study died while taking a similar treatment. Shares of the biopharma firm slid Monday, extending last week's Therapeutics (SRPT) shares continued to slide Monday after the biopharmaceutical firm refused a Food and Drug Administration (FDA) request to stop distributing its Elevidys treatment for muscular dystrophy. The FDA called for the halt after a third patient suffering from a form of muscular dystrophy taking a similar gene therapy to Elevidys in a Phase 1 study died of liver failure, possibly related to the drug. The news of the patient death sent shares of Sarepta plunging Friday. Elevidys has already been approved to treat both ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. Sarepta voluntarily stopped shipments for non-ambulatory patients last month following a second death during the study to gauge the efficacy of the drug for Limb-Girdle muscular dystrophy. The company noted the third patient who died suffered from non-ambulant Limb-Girdle muscular dystrophy. However, Sarepta said that because its comprehensive scientific interpretation of the data 'shows no new or changed safety signals in the ambulant patient population, we will continue to ship ELEVIDYS to the ambulant population.' Sarepta said it's looking to 'continued discussions and sharing of information with FDA in order to advance our shared purpose of protecting patient safety and informed access to care." Shares of Sarepta were down about 3% in recent trading. They've lost nearly 90% of their value since the start of the year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
